Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Peak Frameworks

SEPTEMBER 19, 2023

For example, in the 2012 Facebook IPO, common shareholders gained exposure to the tech giant's fortunes, while also securing a say in corporate matters. By virtue of their ownership, they possess a direct financial interest in the company's success. The private equity firms involved had to navigate a storm of stakeholder concerns.

Corporation 52

Corporation Private Equity Mergers and Acquisitions Corporate Finance 52

Mergers and Inquisitions

NOVEMBER 1, 2023

Advanced Financial Modeling : There’s a case study on Jazz Pharmaceuticals if you’re more interested in that vertical. What about when the IPO market is shut down and exits look uncertain? Life science-oriented roles in VC and growth firms will also be fine because there’s always demand for new biotech and pharmaceutical products.

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

M&A Leadership Council

AUGUST 15, 2022

In a follow-up study for the 10 largest mergers of 1985, the author of this book found that only a minority of the deals had ended in a divestiture even after 20 years – and most of the divestitures were partial. Sometimes spin-offs precede mergers. Yet in major companies, the level appears to be lower. Recent U.S.

Mergers and Acquisitions 52

Mergers and Acquisitions IPO M&A Initial Public Offering 52

Cooley M&A

JANUARY 22, 2021

The second half of the year witnessed a rebound spurred by several multibillion-dollar deals, including Gilead’s acquisition of Immunomedics for nearly $21 billion and AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39 billion. Life Sciences Enters the SPAC Party, But Will Reverse Merger Suitors Join In?

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40